Sleep deprivation may favor the onset of psychiatric disorders

The “ Sleep&Psyche” project dedicated to psychiatry specialists

Thanks to the contribution of Fidia Farmaceutici, the 2019 edition of the Sleep& Psyche Project (Progetto Sonno & Psiche) has been launched.
The project will involve specialists in the field of psychiatry, focusing on the impact of sleep disorders on patients affected by psychiatric conditions, to provide the most appropriate treatment, and consists in 4 training days, between January and November 2019.

The role of circadian rhythmicity

Disruption of sleep and circadian rhythmicity have been linked with an increased susceptibility to mood disorders and, in general, with decreased wellbeing outcomes. According to an article in the July 25, 2018 issue of JAMA Psychiatry, in which the neural mechanisms underlying insomnia were identified for the first time, poor sleep quality and depressive symptoms are associated with functional connectivity between the areas of the brain associated with short-term memory (dorsolateral prefrontal cortex), self (precuneus) and negative emotions (lateral orbitofrontal cortex). This causes the sufferers to dwell on bad thoughts, leading to a poor quality of sleep.

Findings from recent studies have demonstrated the close relationship between disruption of the sleep-wake cycle and chronic conditions


Find out more about Fidia’s product portfolio:

Go to the website


Fidia Farmaceutici has a specific module dedicated to Pharmaco-Vigilance in order to promptly reporting of suspected adverse reactions. If you suspect that you have had an adverse reaction while taking one of our products or you have found defects

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine